M&A Deal Summary

Aratana Therapeutics Acquires Vet Therapeutics

On October 14, 2013, Aratana Therapeutics acquired life science company Vet Therapeutics for 30M USD

Acquisition Highlights
  • This is Aratana Therapeutics’ 1st transaction in the Life Science sector.
  • This is Aratana Therapeutics’ largest (disclosed) transaction.
  • This is Aratana Therapeutics’ 1st transaction in the United States.
  • This is Aratana Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2013-10-14
Target Vet Therapeutics
Sector Life Science
Buyer(s) Aratana Therapeutics
Deal Type Add-on Acquisition
Deal Value 30M USD

Target

Vet Therapeutics

Del Mar, California, United States
Vet Therapeutics, Inc. develops and sells antibody-based therapies.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aratana Therapeutics

Leawood, Kansas, United States
Category Company
Founded 2010
Sector Life Science
Employees83
Revenue 35M USD (2018)
DESCRIPTION

Aratana Therapeutics, Inc. is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana Therapeutics, Inc. was formed in 2010 and is headquartered in Leawood, Kansas.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 2
State (California) 1 of 1
Country (United States) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-01-06 Okapi Sciences NV

Heverlee, Belgium

Okapi Sciences NV is Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.

Buy -
Mergr

Product

Company

Legal